• Transition of CEO role

    Posted on 15 May 2013

    The Board of Photonz Corporation is delighted to announce the appointment of Dr James Campbell to the role of CEO as part of a staged transition that sees Dr Greg Collier assume the CEO role of the ASX-listed biotech company Invion Limited. 

  • Photonz's Chief Scientific Officer Wins NZBIO Award

    Posted on 20 March 2013

    Dr Hywel Griffiths, Chief Scientific Officer for Photonz Corp. was named the 2013 Young Biotechnologist of the Year by NZBIO at an award ceremony Tuesday evening.


  • Seeking commercial partners

    Posted on 9 November 2012

    AUCKLAND via ALGAE WORLD ASIA CONFERENCE SINGAPORE – 8 November 2012 – Talks are underway involving potential partners of Photonz Corporation as the company is finalising its process for manufacturing eicosapentaenoic acid (EPA) by fermentation of micro-algae.


Photonz - producing high purity EPA from algal fermentation

Photonz Corporation is a biotechnology company producing the omega-3 fatty acid eicosapentaenoic acid (EPA) from its primary source, marine microalgae. EPA is a critical ingredient in regulated pharmaceutical products and medicinal foods addressing cardiovascular disease.

Globally there is significant demand for pharmaceuticals using EPA as an active ingredient and this demand is increasing rapidly. Currently, the majority of EPA is extracted from wild fish oil - a limited and variable secondary source at risk of collapse. Photonz bypasses fish oil and any associated contaminants and pollutants and produces EPA directly from a microalgal source through a unique fermentation process, which confers a number of advantages.

Photonz fermentation product PNZ0901, is produced using Photonz' proprietary algal fermentation technology which overcomes a number of obstacles previously encountered in continuous fermentation of microalgae.

The Company owns or controls seven patent families covering fermentation and purification of microalgal EPA.